Skip to main content

Table 1 Baseline clinical and pathologic characteristics of discovery cohort

From: New risk score for predicting steroid resistance in patients with focal segmental glomerulosclerosis or minimal change disease

VariableNo responseResponseOR (95% CI)a
N (%)10 (19.6)41 (80.4)
Age (year)38.2 ± 21.937.8 ± 19.41.001 (0.97–1.04)
Gender (%) male6 (60.0)26 (63.4)1.15 (0.28–4.77)
MAP (mmHg)99.6 ± 17.690.3 ± 18.51.05 (0.99–1.12)
BMI (kg/m2)26.2 ± 5.524.4 ± 5.11.07 (0.93–1.22)
Ln(Pro) (g/24 h)2.1 ± 0.42.0 ± 0.41.53 (0.30–7.79)
Albumin (g/L)17.0 ± 6.714.3 ± 5.51.10 (0.97–1.25)
eGFR (mL/min/1.73 m2)103.5 ± 20.2102.3 ± 30.61.003 (0.97–1.03)
TG (mmol/L)3.1 ± 2.23.2 ± 1.80.98 (0.66–1.47)
TC (mmol/L)8.5 ± 3.810.2 ± 3.10.79 (0.60–1.05)
Ln(MAU) (mg/L)7.9 ± 1.38.5 ± 1.20.62 (0.34–1.13)
Ln(ORM) (mg/g Cr)5.0 ± 1.25.6 ± 1.00.55 (0.27–1.15)
Ln(RBP) (mg/L)− 1.1 ± 1.7− 0.7 ± 1.70.85 (0.55–1.33)
Ln(β2-MG) (ug/L)6.6 ± 1.85.7 ± 1.41.89 (1.02–3.53)#
Ln(α1-MG) (mg/dL)1.6 ± 0.91.3 ± 1.01.40 (0.63–3.04)
Pathology   
 FSGS (%)5 (45.5)6 (54.5)5.83 (1.29–26.46)*
 MCD (%)5 (12.5)35 (87.5)0.17 (0.04–0.78)*
  1. MAP: mean arterial pressure; BMI: body mass index; Ln(Pro): natural logarithm of urine protein; eGFR: estimated glomerular filtration rate; TG: triglyceride; TC: total cholesterol; MAU: microalbumin; ORM: orosomucoid; RBP: retinol binding protein; β2-MG: β2-microglobulin; α1-MG: α1-microglobulin; FSGS: focal segmental glomerulosclerosis; IgAN: Immunoglobulin A nephropathy; MCD: minimal change disease
  2. a Clinical characteristics are adjusted by age and gender
  3. *P < 0.05, #P < 0.01